AbbVie Inc. (ABBV)
Every FINRA and SEC series the site collects for AbbVie Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
19.5M
Short interest
settlement 2026-08-31
4.4
Days to cover
+6.6% vs prior
54.2%
Short share of volume
2026-09-11
13,102
Fails to deliver
settlement 2026-08-13
-$8.2M
Insider flow, 90 days
0 buys, 1 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 31 August 2026, short interest in ABBV is 19,514,024 shares, down 3,033,815 shares over the last month. Over the last 48 readings it ranged from 14,700,538 shares (13 June 2025) to 25,110,220 shares (13 March 2026). At the reported average volume of 4.4M shares a day that is 4.4 days to cover.
Embed this chartkeeps the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/abbv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 19,514,024 | +6.6% | 4,431,865 | 4.40 |
| 2026-08-14 | 18,299,894 | -18.8% | 5,120,103 | 3.57 |
| 2026-07-31 | 22,547,839 | -0.4% | 5,670,476 | 3.98 |
| 2026-07-15 | 22,632,412 | +3.4% | 6,559,915 | 3.45 |
| 2026-06-30 | 21,899,078 | -6.6% | 12,548,298 | 1.75 |
| 2026-06-15 | 23,446,826 | +1.2% | 5,150,656 | 4.55 |
| 2026-05-29 | 23,158,744 | +2.5% | 5,422,513 | 4.27 |
| 2026-05-15 | 22,590,034 | +8.1% | 5,670,258 | 3.98 |
| 2026-04-30 | 20,907,964 | -4.3% | 7,711,618 | 2.71 |
| 2026-04-15 | 21,845,453 | +8.6% | 5,885,786 | 3.71 |
| 2026-03-31 | 20,125,180 | -19.9% | 8,202,339 | 2.45 |
| 2026-03-13 | 25,110,220 | +15.5% | 6,795,131 | 3.70 |
| 2026-02-27 | 21,748,668 | -4.9% | 6,019,787 | 3.61 |
| 2026-02-13 | 22,876,092 | +16.2% | 8,360,159 | 2.74 |
| 2026-01-30 | 19,684,551 | -10.7% | 7,106,876 | 2.77 |
| 2026-01-15 | 22,042,536 | +11.9% | 7,499,512 | 2.94 |
| 2025-12-31 | 19,705,568 | +9.0% | 5,136,946 | 3.84 |
| 2025-12-15 | 18,075,534 | -0.7% | 5,046,976 | 3.58 |
| 2025-11-28 | 18,209,156 | -2.8% | 6,345,817 | 2.87 |
| 2025-11-14 | 18,724,102 | -0.9% | 6,259,695 | 2.99 |
| 2025-10-31 | 18,891,139 | +4.5% | 5,096,113 | 3.71 |
| 2025-10-15 | 18,080,904 | +11.0% | 6,937,881 | 2.61 |
| 2025-09-30 | 16,289,679 | -1.6% | 6,278,492 | 2.59 |
| 2025-09-15 | 16,559,691 | +7.5% | 4,667,989 | 3.55 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of ABBV volume is 54.2%, up 4.6 points over the last five sessions. Over the last 52 readings it ranged from 22.4% (7 August 2026) to 71.0% (20 August 2026). The latest reading is 5.0 points above the 30-session average of 49.2%, on 1.6M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 881K | 1.6M | 54.2% | 1,364 |
| 2026-09-10 | 939K | 1.4M | 67.5% | 809 |
| 2026-09-09 | 545K | 1.1M | 47.7% | 2,256 |
| 2026-09-08 | 985K | 1.5M | 64.6% | 312 |
| 2026-09-04 | 968K | 1.5M | 64.4% | 2,404 |
| 2026-09-03 | 453K | 913K | 49.6% | 1,623 |
| 2026-09-02 | 644K | 1.6M | 39.5% | 9,905 |
| 2026-09-01 | 667K | 1.3M | 50.3% | 9,366 |
| 2026-08-31 | 545K | 1.0M | 52.1% | 245 |
| 2026-08-28 | 596K | 1.3M | 45.5% | 1,254 |
| 2026-08-27 | 651K | 1.3M | 48.4% | 955 |
| 2026-08-26 | 581K | 1.2M | 48.8% | 477 |
| 2026-08-25 | 534K | 984K | 54.2% | 10 |
| 2026-08-24 | 662K | 1.1M | 61.0% | 1 |
| 2026-08-21 | 930K | 1.4M | 66.1% | 3,315 |
| 2026-08-20 | 1.4M | 1.9M | 71.0% | 1,129 |
| 2026-08-19 | 1.2M | 2.2M | 55.4% | 19,606 |
| 2026-08-18 | 1.0M | 1.8M | 55.9% | 19,061 |
| 2026-08-17 | 404K | 1.1M | 35.2% | 170 |
| 2026-08-14 | 757K | 1.3M | 57.8% | 11,340 |
| 2026-08-13 | 684K | 1.6M | 41.7% | 33,694 |
| 2026-08-12 | 719K | 1.6M | 45.6% | 5,596 |
| 2026-08-11 | 824K | 1.6M | 52.7% | 25,560 |
| 2026-08-10 | 445K | 1.1M | 40.0% | 4,024 |
| 2026-08-07 | 259K | 1.2M | 22.4% | 9,104 |
| 2026-08-06 | 428K | 1.5M | 28.1% | 382 |
| 2026-08-05 | 529K | 1.8M | 28.9% | 3,145 |
| 2026-08-04 | 1.1M | 2.9M | 36.8% | 725 |
| 2026-08-03 | 1.1M | 2.8M | 39.6% | 8,890 |
| 2026-07-31 | 1.2M | 2.4M | 50.1% | 2,849 |
Fails to deliver
SEC, by settlement date. JSONAs of 13 August 2026, the fails-to-deliver balance in ABBV is 13,102 shares, up 13,099 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (9 February 2026) to 297,246 shares (23 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-13 | 13,102 | $248.76 | $3.3M |
| 2026-08-06 | 3 | $246.20 | $739 |
| 2026-08-04 | 27 | $245.10 | $7K |
| 2026-07-28 | 9 | $256.91 | $2K |
| 2026-07-27 | 9 | $259.36 | $2K |
| 2026-07-15 | 26,659 | $244.78 | $6.5M |
| 2026-07-13 | 2,297 | $248.08 | $570K |
| 2026-07-10 | 529 | $249.91 | $132K |
| 2026-07-07 | 18,801 | $254.76 | $4.8M |
| 2026-07-06 | 29,055 | $261.07 | $7.6M |
| 2026-07-02 | 18,819 | $251.06 | $4.7M |
| 2026-06-30 | 5,541 | $254.31 | $1.4M |
| 2026-06-29 | 6,047 | $253.35 | $1.5M |
| 2026-06-26 | 10 | $243.14 | $2K |
| 2026-06-25 | 13,443 | $234.89 | $3.2M |
| 2026-06-24 | 5 | $234.76 | $1K |
| 2026-06-23 | 199 | $230.01 | $46K |
| 2026-06-18 | 168 | $221.23 | $37K |
| 2026-06-15 | 80 | $227.73 | $18K |
| 2026-06-05 | 503 | $224.94 | $113K |
| 2026-06-04 | 70,982 | $217.13 | $15.4M |
| 2026-06-02 | 35 | $212.93 | $7K |
| 2026-06-01 | 100 | $217.72 | $22K |
| 2026-05-18 | 1,100 | $210.39 | $231K |
| 2026-05-07 | 21 | $205.03 | $4K |
| 2026-05-04 | 32 | $206.60 | $7K |
| 2026-05-01 | 259 | $211.32 | $55K |
| 2026-04-29 | 92,445 | $197.69 | $18.3M |
| 2026-04-22 | 47 | $205.12 | $10K |
| 2026-04-15 | 285 | $210.26 | $60K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at ABBV reported 1 open-market sell worth $8.2M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) on 2026-08-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Sell | 33K | $250.00 | $8.2M | 74K |
| 2026-08-14 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Option exercise | 33K | $79.02 | $2.6M | 107K |
| 2026-05-08 | Quaggin Susan E | n/a | Grant | 1K | $0.00 | $0 | 4K |
| 2026-05-08 | Davis Jennifer L. | n/a | Grant | 1K | $0.00 | $0 | 4K |
| 2026-05-08 | MEYER MELODY B | n/a | Grant | 1K | $0.00 | $0 | 18K |
| 2026-05-08 | BURNSIDE WILLIAM H.L. | n/a | Grant | 1K | $0.00 | $0 | 28K |
| 2026-05-08 | Hart Brett J | n/a | Grant | 1K | $0.00 | $0 | 21K |
| 2026-05-08 | Roberts Rebecca B | n/a | Grant | 1K | $0.00 | $0 | 15K |
| 2026-05-08 | FREYMAN THOMAS C | n/a | Grant | 1K | $0.00 | $0 | 128K |
| 2026-05-08 | WADDELL FREDERICK H | n/a | Grant | 1K | $0.00 | $0 | 30K |
| 2026-05-08 | FALK THOMAS J | n/a | Grant | 1K | $0.00 | $0 | 2K |
| 2026-05-08 | RAPP EDWARD J | n/a | Grant | 1K | $0.00 | $0 | 46K |
| 2026-05-08 | AUSTIN ROXANNE S | n/a | Grant | 1K | $0.00 | $0 | 40K |
| 2026-03-04 | Purdue David Ryan | SVP, Controller | Sell | 5K | $233.56 | $1.2M | 3K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 3K | $235.26 | $612K | 5K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 10K | $234.66 | $2.4M | 7K |
| 2026-03-02 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 6K | $233.51 | $1.3M | 18K |
| 2026-02-27 | Purdue David Ryan | SVP, Controller | Tax withholding | 2K | $232.08 | $489K | 8K |
| 2026-02-27 | Purdue David Ryan | SVP, Controller | Tax withholding | 3K | $232.08 | $625K | 8K |
| 2026-02-27 | Thakkar Roopal | EVP, R&D and CSO | Tax withholding | 8K | $232.08 | $1.9M | 52K |
| 2026-02-27 | Siatis Perry C | EVP, GC AND SECRETARY | Tax withholding | 15K | $232.08 | $3.4M | 23K |
| 2026-02-27 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Tax withholding | 22K | $232.08 | $5.0M | 39K |
| 2026-02-27 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Tax withholding | 13K | $232.08 | $3.0M | 74K |
| 2026-02-27 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Tax withholding | 24K | $232.08 | $5.5M | 83K |
| 2026-02-27 | Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO | Tax withholding | 37K | $232.08 | $8.5M | 179K |
| 2026-02-27 | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Tax withholding | 16K | $232.08 | $3.8M | 198K |
| 2026-02-27 | Crum Demetris D | EVP, CHIEF HR OFFICER | Tax withholding | 2K | $232.08 | $370K | 8K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Sell | 22K | $230.00 | $5.1M | 38K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Option exercise | 7K | $192.86 | $1.4M | 61K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Option exercise | 8K | $175.28 | $1.4M | 53K |
| 2026-02-25 | Siatis Perry C | EVP, GC AND SECRETARY | Option exercise | 7K | $149.62 | $1.1M | 45K |
| 2026-02-18 | Crum Demetris D | EVP, CHIEF HR OFFICER | Grant | 1K | $0.00 | $0 | 10K |
| 2026-02-18 | Crum Demetris D | EVP, CHIEF HR OFFICER | Grant | 1K | $0.00 | $0 | 8K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 1K | $0.00 | $0 | 11K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 1K | $0.00 | $0 | 9K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 890 | $0.00 | $0 | 8K |
| 2026-02-18 | Purdue David Ryan | SVP, Controller | Grant | 3K | $0.00 | $0 | 7K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 7K | $0.00 | $0 | 60K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 3K | $0.00 | $0 | 54K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 2K | $0.00 | $0 | 50K |
| 2026-02-18 | Thakkar Roopal | EVP, R&D and CSO | Grant | 6K | $0.00 | $0 | 48K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 38K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 32K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 6K | $0.00 | $0 | 27K |
| 2026-02-18 | Siatis Perry C | EVP, GC AND SECRETARY | Grant | 16K | $0.00 | $0 | 21K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 7K | $0.00 | $0 | 60K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 8K | $0.00 | $0 | 53K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 9K | $0.00 | $0 | 46K |
| 2026-02-18 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Grant | 25K | $0.00 | $0 | 37K |
| 2026-02-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Grant | 6K | $0.00 | $0 | 87K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
13F holders
Tracked managers holding ABBV at their latest 13F. JSON8 of the 30 tracked managers held ABBV at their latest 13F, $5.90B in total at quarter-end prices. Fisher Asset Management is the largest at $2.39B (0.7% of its portfolio) as of 2026-06-30. Over the prior quarter 7 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 9.5M | $2.39B | 0.71% | +406K |
| Citadel Advisors | 2026-06-30 | 6.6M | $1.65B | 0.19% | +2.8M |
| D. E. Shaw & Co. | 2026-06-30 | 2.4M | $616.4M | 0.29% | +1.5M |
| Millennium Management | 2026-06-30 | 2.3M | $569.6M | 0.21% | +586K |
| AQR Capital Management | 2026-06-30 | 2.0M | $507.1M | 0.18% | +1.1M |
| Point72 Asset Management | 2026-06-30 | 388K | $97.7M | 0.11% | +348K |
| Two Sigma Investments | 2026-06-30 | 262K | $65.8M | 0.05% | +42K |
| Bridgewater Associates | 2026-06-30 | 12K | $3.0M | 0.01% | -19K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) AbbVie Inc. reported revenue of $16.99B, up 10.2% from the same quarter a year earlier, and net income of $3.61B (2.03 diluted EPS). In FY 2025 it generated $19.03B of operating cash flow and spent $980.0M on buybacks and $11.66B on dividends.
- Cash
- $6.57B
- Equity
- -$5.93B
- Total assets
- $135.12B
- Shares outstanding
- 1,767,117,285
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.99B | $3.61B | 21.3% | 2.03 |
| Q1 2026 | 2026-03-31 | $15.00B | $695.0M | 4.6% | 0.39 |
| Q4 2025 | 2025-12-31 | $16.62B | $1.82B | 10.9% | 1.02 |
| Q3 2025 | 2025-09-30 | $15.78B | $186.0M | 1.2% | 0.10 |
| Q2 2025 | 2025-06-30 | $15.42B | $938.0M | 6.1% | 0.52 |
| Q1 2025 | 2025-03-31 | $13.34B | $1.29B | 9.6% | 0.72 |
| Q4 2024 | 2024-12-31 | $15.10B | -$22.0M | -0.1% | -0.02 |
| Q3 2024 | 2024-09-30 | $14.46B | $1.56B | 10.8% | 0.88 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $61.16B | $4.23B | $19.03B | $1.21B | $980.0M | $11.66B |
| FY 2024 | 2024-12-31 | $56.33B | $4.28B | $18.81B | $974.0M | $1.71B | $11.03B |
| FY 2023 | 2023-12-31 | $54.32B | $4.86B | $22.84B | $777.0M | $1.97B | $10.54B |
| FY 2022 | 2022-12-31 | $58.05B | $11.84B | $24.94B | $695.0M | $1.49B | $10.04B |
| FY 2021 | 2021-12-31 | $56.20B | $11.54B | $22.78B | $787.0M | $934.0M | $9.26B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
AbbVie Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows AbbVie Inc. (ABBV), SEC CIK 1551152, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1551152Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 14 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- REGNREGENERON PHARMACEUTICALS, INC.
- LLYELI LILLY & Co
- VRTXVERTEX PHARMACEUTICALS INC / MA
- ALNYALNYLAM PHARMACEUTICALS, INC.
- BMYBRISTOL MYERS SQUIBB CO
- CYTKCYTOKINETICS INC
- PTCTPTC THERAPEUTICS, INC.
- INSMINSMED Inc
- IONSIONIS PHARMACEUTICALS INC
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- JNJJOHNSON & JOHNSON
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- ABTABBOTT LABORATORIES
- BBIOBridgeBio Pharma, Inc.
- KNSAKiniksa Pharmaceuticals International, plc
- JAZZJazz Pharmaceuticals plc
- ARQTArcutis Biotherapeutics, Inc.
- VTRSViatris Inc
- PRGOPERRIGO Co plc
- DYNDyne Therapeutics, Inc.
- ARDXARDELYX, INC.
Datasets
Frequently Asked Questions
How much of ABBV is sold short?
What is ABBV's daily short volume?
Does ABBV have fails to deliver?
Are ABBV insiders buying or selling?
What did ABBV report last quarter?
Which funds hold ABBV?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.